ライフサイエンスコーパス: endogenous cannabinoid

1 ed increased responses to elevated levels of endogenous cannabinoids.

2 and immunological actions of Delta(9)THC and endogenous cannabinoids.

3 ating the cognitive actions of marijuana and endogenous cannabinoids.

4 t it is mediated by the autocrine release of endogenous cannabinoids.

5 smission that involves the production of the endogenous cannabinoid 2-arachidonoyl glycerol (2-AG).

6 rrelation between enhanced production of the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) and

7 ility to demonstrate a critical role for the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) in

8 The endogenous cannabinoid 2-arachidonoylglycerol (2-AG) is

9 embrane serine hydrolase that hydrolyzes the endogenous cannabinoid 2-arachidonoylglycerol (2-AG) to

10 iatal levels of AEA, but not the other major endogenous cannabinoid 2-arachidonoylglycerol (2-AG), du

11 e demonstrate that rat platelets contain the endogenous cannabinoid 2-arachidonyl glyceride (2-AG), a

12 Endogenous cannabinoids acting at CB(1) receptors stimul

13 rstanding how exogenous (e.g., cannabis) and endogenous cannabinoids affect behavior.

14 ting fatty acid amides including anandamide (endogenous cannabinoid agonist) and oleamide (sleep-indu

15 nsible for the degradation of anandamide, an endogenous cannabinoid agonist, and oleamide, a sleep-in

16 ylglycerol (2-AG) are the most characterized endogenous cannabinoids (also known as endocannabinoids)

17 The endogenous cannabinoid anandamide (AEA) is a lipid media

18 The endogenous cannabinoid anandamide (N-arachidonoylethanol

19 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing

20 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing

21 omodulatory fatty acid amides, including the endogenous cannabinoid anandamide and the sleep-inducing

22 yme that degrades lipid amides including the endogenous cannabinoid anandamide and the sleep-inducing

23 lass of lipid transmitters that includes the endogenous cannabinoid anandamide and the sleep-inducing

24 ogenous signaling lipids, which includes the endogenous cannabinoid anandamide and the sleep-inducing

25 or the uptake and cellular processing of the endogenous cannabinoid anandamide are not well understoo

26 cilitated transport process that removes the endogenous cannabinoid anandamide from extracellular spa

27 The endogenous cannabinoid anandamide has recently been iden

28 permitted measurement of the release of the endogenous cannabinoid anandamide in the periaqueductal

29 The endogenous cannabinoid anandamide is removed from the sy

30 to the synthetic cannabinoid HU-210 and the endogenous cannabinoid anandamide led to significant ind

31 These findings indicate that the endogenous cannabinoid anandamide plays an important rol

32 We also observed that endogenous cannabinoid anandamide was able to reduce hep

33 cluding known signaling molecules (e.g., the endogenous cannabinoid anandamide) and a novel family of

34 Although structurally related to the endogenous cannabinoid anandamide, OEA does not bind to

35 nzyme responsible for the degradation of the endogenous cannabinoid anandamide.

36 tions of polyunsaturated NAEs, including the endogenous cannabinoid anandamide.

37 class of signaling lipids that includes the endogenous cannabinoid anandamide.

38 binoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl g

39 id effect was mimicked by application of the endogenous cannabinoid, anandamide and blocked by VR1 an

40 Methanandamide (an analog of an endogenous cannabinoid, anandamide) also reduced cell su

41 The two main endogenous cannabinoids, anandamide and 2-arachidonoyl g

42 achidonoylglycerol (2-AG), the most abundant endogenous cannabinoid and a full agonist for cannabinoi

43 s in the CNS is indicated by the presence of endogenous cannabinoids and cannabinoid receptors.

44 ing cannabinoid receptors using exogenous or endogenous cannabinoids and use of FAAH inhibitors may c

45 platelets and macrophages generate different endogenous cannabinoids, and that both 2-AG and anandami

46 is thought that the physiological actions of endogenous cannabinoid arachidonylethanolamide (AEA), as

47 porting a possible physiological role for an endogenous cannabinoid, arachidonylethanolamide (AEA, an

48 The best-studied endogenous cannabinoids are 2-arachidonoyl glycerol and

49 Moreover, endogenous cannabinoids are physiological immune regulat

50 endocrine output, presaging the emergence of endogenous cannabinoids as important signalling molecule

51 stem consisting of cannabinoid receptors and endogenous cannabinoids as well as the enzymatic machine

52 However, the endogenous cannabinoids, as well as Delta(9)-tetrahydroc

53 to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation

54 Both exogenous and endogenous cannabinoids can allosterically modulate glyc

55 In contrast to classical neurotransmitters, endogenous cannabinoids can function as retrograde synap

56 Endogenous cannabinoids can thereby rapidly enhance inhi

57 regnancy has the potential to interfere with endogenous cannabinoid (CB) regulation of fetal nervous

58 en reported to be activated by exogenous and endogenous cannabinoid compounds but surprisingly also b

59 delta9-Tetrahydrocannabinol and endogenous cannabinoids (e.g., anandamide) initiate thei

60 Pharmacological augmentation of endogenous cannabinoid (eCB) signaling has been suggeste

61 correlates that accompany the disruption of endogenous cannabinoid (eCB) signaling in a food-motivat

62 Augmentation of endogenous cannabinoid (eCB) signaling represents an eme

63 Anxiety is further modulated by the endogenous cannabinoid (eCB) system that attenuates the

64 presents a primary degradation enzyme of the endogenous cannabinoid (eCB), 2-arachidonoyglycerol (2-A

65 t GABAergic inhibition in DGCs is subject to endogenous cannabinoid (eCB)-mediated retrograde regulat

66 The oxygenation of endogenous cannabinoids (eCBs) 2-arachidonoyl glycerol (

67 e current study to investigate if intraislet endogenous cannabinoids (ECs) regulate beta-cell prolife

68 The cellular inactivation of the endogenous cannabinoid (endocannabinoid) anandamide (AEA

69 acid amide hydrolase (FAAH) inactivates the endogenous cannabinoid (endocannabinoid) anandamide and

70 Endogenous cannabinoids (endocannabinoids) are endogenou

71 The endogenous cannabinoids (endocannabinoids) are lipid mol

72 Endogenous cannabinoids (endocannabinoids) are small mol

73 Retrograde synaptic signaling by endogenous cannabinoids (endocannabinoids) is a recently

74 ly inhibited by cannabinoids in the NAc, and endogenous cannabinoids (endocannabinoids) play a critic

75 m potentiation (LTP) in the hippocampus, yet endogenous cannabinoids (endocannabinoids) transiently s

76 The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzy

77 omprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzy

78 Endogenous cannabinoids (endocannabinoids, eCBs) are ubi

79 t in vitro studies have described a role for endogenous cannabinoids ("endocannabinoids") as transsyn

80 The signaling capacity of endogenous cannabinoids ("endocannabinoids") is tightly

81 nnabis, and mediate physiological effects of endogenous cannabinoids ('endocannabinoids').

82 Thus, 2-arachidonylglycerol, a putative endogenous cannabinoid ester, also may serve as a substr

83 Exogenous as well as endogenous cannabinoids have been shown to target voltag

84 (2-AG) and depolarization-induced release of endogenous cannabinoids have minimal effect on mIPSC fre

85 findings suggest that Purkinje cells release endogenous cannabinoids in response to elevated calcium,

86 these findings suggest a widespread role for endogenous cannabinoids in retrograde synaptic inhibitio

87 Recent research has suggested a role for endogenous cannabinoids in the descending inhibition of

88 ese experiments argue for the involvement of endogenous cannabinoids in time estimation.

89 l cells were treated with both synthetic and endogenous cannabinoids in vitro, and biochemical coupli

90 The endogenous cannabinoids, including the closely related l

91 se findings strongly suggest that release of endogenous cannabinoids is involved in brain reward proc

92 nt, retrograde inhibition of GABA release by endogenous cannabinoids is persistently enhanced in the

93 The endogenous cannabinoid ligand anandamide is biosynthesiz

94 2-AG is the most prevalent endogenous cannabinoid ligand in the brain, and electrop

95 Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous sys

96 Anandamide is an endogenous cannabinoid ligand, and its levels are spatio

97 Anandamide, an endogenous cannabinoid ligand, binds to CB1 cannabinoid

98 Endogenous cannabinoid ligands (endocannabinoids) produc

99 of anandamide (arachidonylethanolamide), an endogenous cannabinoid lipid, are terminated by a two-st

100 The effect of SR 141716A suggests that an endogenous cannabinoid may mediate striato-nigral transm

101 vel of the thalamus and that one function of endogenous cannabinoids may be to modulate pain sensitiv

102 y CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of

103 If endogenous cannabinoids modulate basal nociceptive thres

104 141716A was used to test the hypothesis that endogenous cannabinoids modulate tonic pain sensitivity.

105 plays a central role in the lifecycle of the endogenous cannabinoid N-arachidonoylethanolamine (anand

106 deducing the bioactive conformation of these endogenous cannabinoids, not only at the CB receptors bu

107 rform a comparative study with synthetic and endogenous cannabinoids on their effects on synaptic con

108 Endogenous cannabinoids play a central role in the modul

109 These findings suggest that exogenous and endogenous cannabinoids potentiate GlyRs via a hydrogen

110 oactive ingredients in marijuana, as well as endogenous cannabinoids produced in the brain.

111 suggests an additional mode of regulation of endogenous cannabinoid receptor activity.

112 The endogenous cannabinoid receptor agonist anandamide is pr

113 and this molecule is well established as an endogenous cannabinoid receptor agonist in the brain.

114 The present study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylg

115 Several analogues of the endogenous cannabinoid receptor ligand arachidonylethano

116 These amides were compared to the endogenous cannabinoid receptor ligand arachidonylethano

117 ated oxygenases capable of metabolizing this endogenous cannabinoid receptor ligand.

118 of arachidonylethanolamide (anandamide), an endogenous cannabinoid receptor ligand.

119 cologic effects, and has been proposed as an endogenous cannabinoid receptor ligand.

120 Although endogenous cannabinoid receptors (CB(1)Rs) are abundantl

121 ction of THC is specific (i.e., mediated via endogenous cannabinoid receptors) or non-specific, refle

122 lation of appetite hormones mediated through endogenous cannabinoid receptors, independent of glucose

123 We measured endogenous cannabinoid release in dorsal striatum of fre

124 ting that retrograde synaptic suppression by endogenous cannabinoids represents a widespread signalin

125 e (FAAH), which leads to increased levels of endogenous cannabinoids, resulted in decreased liver inj

126 rotransmission, raising the possibility that endogenous cannabinoids serve naturally to modulate pain

127 These findings suggest that endogenous cannabinoids serve naturally to modulate the

128 Anandamide, an endogenous cannabinoid signaling molecule, in a concentr

129 e consistent with a neuroprotective role for endogenous cannabinoid signaling pathways and with a pot

130 Endogenous cannabinoid signaling pathways have been impl

131 These findings indicate that endogenous cannabinoid signaling pathways protect mice f

132 olar cells suggest a substantive role for an endogenous cannabinoid signaling system in retinal physi

133 iterature on the effects of cannabinoids and endogenous cannabinoid signaling systems in the regulati

134 nisms of action, including a facilitation of endogenous cannabinoid signaling via one of its metaboli

135 sites offer novel targets for modulation of endogenous cannabinoid signalling.

136 Here, we test the hypothesis that the endogenous cannabinoid sn-2-arachidonoylglycerol (2-AG)

137 ication and quantification of anandamide, an endogenous cannabinoid substance, and other fatty acid e

138 anandamide (N-arachidonoylethanolamine), an endogenous cannabinoid substance, may be produced throug

139 Anandamide, an endogenous cannabinoid substance, suppresses the potassi

140 view of the possible role of these lipids as endogenous cannabinoid substances.

141 the release of anandamide, but not of other endogenous cannabinoids such as 2-arachidonylglycerol.

142 ls, but there is only indirect evidence that endogenous cannabinoids such as anandamide participate i

143 The IPSCs are regulated by exogenous and endogenous cannabinoids, suggesting that they arise from

144 GAD(67)-mediated GABA synthesis by reducing endogenous cannabinoid suppression of GABA release.

145 link between functional abnormalities in the endogenous cannabinoid system and drug abuse and depende

146 The endogenous cannabinoid system appears to serve vascular,

147 The endogenous cannabinoid system has been implicated in dru

148 Although emerging evidence implicates the endogenous cannabinoid system in aspects of opioid and e

149 Investigations of the endogenous cannabinoid system in the prefrontal cortex o

150 To evaluate the role of the endogenous cannabinoid system in the regulation of basal

151 results suggest that neuroadaptations in the endogenous cannabinoid system may be part of the neuropl

152 ing SR141716A and SR144528 indicate that the endogenous cannabinoid system may be tonically active in

153 These results indicate that the endogenous cannabinoid system may represent a potential

154 Although the endogenous cannabinoid system modulates a variety of phy

155 butable to the disruption by cannabis of the endogenous cannabinoid system's spatiotemporal regulatio

156 uding disturbances in the development of the endogenous cannabinoid system, are discussed.

157 wal has been established via discovery of an endogenous cannabinoid system, identification of cannabi

158 suggesting a role for this oxygenase in the endogenous cannabinoid system.

159 re mediated by receptors that are part of an endogenous cannabinoid system.

160 Given that the endogenous cannabinoid (that is, endocannabinoid) system

161 n, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycer

162 mponent found in marijuana or anandamide, an endogenous cannabinoid, to DC cultures induced apoptosis

163 investigation uncovered a specific role for endogenous cannabinoid tone in timing behavior, as eleva

164 of anandamide signaling in vivo, setting an endogenous cannabinoid tone that modulates pain percepti

165 We also show that endogenous cannabinoids tonically regulate pain threshol

166 udies have demonstrated that the majority of endogenous cannabinoid type 1 (CB(1)) receptors do not r

167 Using GC/MS to detect possible endogenous cannabinoids, we found 3 nmol of 2-arachidony